DVAX:NSD-Dynavax Technologies Corporation (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 12.84

Change

+0.01 (+0.08)%

Market Cap

USD 1.69B

Volume

0.33M

Analyst Target

USD 15.33
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
VTRS Viatris Inc

-0.09 (-0.72%)

USD 15.08B
NBIX Neurocrine Biosciences Inc

-0.46 (-0.34%)

USD 12.97B
ITCI Intracellular Th

+1.24 (+1.48%)

USD 8.85B
LNTH Lantheus Holdings Inc

+0.29 (+0.32%)

USD 6.19B
ALKS Alkermes Plc

+0.15 (+0.51%)

USD 5.01B
ALVO Alvotech

+0.04 (+0.32%)

USD 3.47B
HCM HUTCHMED DRC

+0.05 (+0.35%)

USD 2.94B
AMPH Amphastar P

-0.85 (-2.17%)

USD 2.09B
SUPN Supernus Pharmaceuticals Inc

+0.01 (+0.03%)

USD 2.05B
EVO Evotec SE ADR

+0.54 (+12.11%)

USD 1.70B

ETFs Containing DVAX

HVAX:CA 4.23 % 0.00 %

N/A

N/A
GERM 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -8.15% 57% F 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.15% 57% F 39% F
Trailing 12 Months  
Capital Gain -8.48% 58% F 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.48% 58% F 39% F
Trailing 5 Years  
Capital Gain 113.64% 91% A- 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 113.64% 91% A- 87% B+
Average Annual (5 Year Horizon)  
Capital Gain 66.59% 84% B 90% A-
Dividend Return 66.59% 84% B 90% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 156.76% 22% F 15% F
Risk Adjusted Return 42.48% 86% B+ 72% C
Market Capitalization 1.69B 85% B 77% C+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.